中药复方溶液环境对黄连生物碱大孔树脂吸附的动力学比较研究

研究含黄连的不同中药复方水提液溶液环境对大孔树脂吸附率的影响,为大孔树脂在中药生产中的优选和在中药复方精制分离技术中的推广应用提供实验依据。采用pH、电导率、盐度、浊度、黏度5项物理化学指标性参数表征6种复方水提液体系,通过比较黄连生物碱于不同溶液环境中对相同AB-8树脂的吸附动力学变化,考察溶液环境对复方中指标性成分分离纯化的影响。实验结果表明,黄连在不同中药复方配伍中,虽然溶液环境差异较大,但黄连中生物碱类成分均可以在树脂上被选择性吸附,复方1~6指标性生物碱成分达到吸附平衡的时间均有差异;复方2的电导率和盐度较大,生物碱与大孔树脂的吸附作用显著降低,复方6的电导率小而黏度较大,生物碱达到吸附平衡的时间较其他复方长,吸附作用大于复方2而较其他复方较小。上述研究结果表明,复方水溶液的电导率、盐度为影响生物碱在大孔树脂选择性吸附的主要因素,黏度影响生物碱达到吸附平衡的时间。     

山豆根和北豆根挥发性成分的对比分析

采用GC-MS对山豆根和北豆根的挥发性化学成分进行了分析。通过谱图检索和解析,从山豆根中确定了35种挥发性成分,从北豆根中确定了31种。其中北豆根中的化合物类型较多,含氮化合物和含氧杂环化合物明显较北豆根多。两种中草药中量最多的都是脂肪酸,但山豆根为十八碳二烯酸、十六碳酸和六碳酸;北豆根为十三碳烯酸。     

Comparative pharmacokinetic study of nine bioactive components in osteoarthritis rat plasma using ultra-performance liquid chromatography–tandem mass spectrometry after single and combined oral administration of Epimedii Folium and Chuanxiong Rhizoma extracts

The herb pair Epimedii Folium–Chuanxiong Rhizoma (EF–CR), derived from the classical traditional Chinese medicine ‘Xian Ling Pi San’, has a distinctive compatibility therapeutic profile and is clinically safe and effective. This study aimed to investigate and compare the pharmacokinetic characteristics of nine analytes in osteoarthritis (OA) rat plasma after the oral administration of EF, CR or a combination of these two herbs. We developed an ultra-performance liquid chromatography method coupled with quadrupole linear ion-trap mass spectrometry to simultaneously quantify and assess the pharmacokinetics of icariin, epimedin A, epimedin B, epimedin C, icariside I, icariside II, ferulic acid, ligustilide and senkyunolide A of the EF–CR pair in the plasma of osteoarthritic rats. The pharmacokinetic parameters showed that the absorption of multiple components was significantly enhanced and residence time was prolonged in the EF–CR group (P < 0.05) compared to the single-herb group. These parameters revealed that the combination of EF and CR exhibited synergistic effects of the nine bioactive components, suggesting the potential application of the EF–CR combination for the treatment of OA.     

Kinetic features of Gualou-Xiebai-Banxia decoction,a classical traditional Chinese medicine formula,in rat plasma and intestine content based on its metabolic profile

Gualou-Xiebai-Banxia decoction (GXB) is a famous classical traditional Chinese medicine (TCM) formula for the treatment of coronary heart disease (CHD, namely chest stuffiness and pain syndrome in Chinese medicine). Compared with Gualou-Xiebai-Baijiu decoction, which only consists of Trichosanthis Pericarpium (TP), Allii Macrostemonis Bulbus (AMB) and wine, GXB comprises one additional herbal medicine, Pinellinae Rhizoma Praeparatum (PRP). However, due to a lack of kinetic profile studies on GXB, its in vivo components with high exposure remain unknown, making it difficult to interpret bioactive components likely linked to its efficacy, but also fails to provide substance-related evidence for reflecting the compatibility in GXB. The goal of this study was to systematically characterize the kinetic features of GXB in rat plasma and intestine content for revealing its in vivo high-exposure components on the basis of their metabolic fates, and to compare the kinetic differences between GXB and GXB-dePRP (GXB deducted PRP) for describing the chemical contribution of PRP to the compatibility in GXB. Firstly, the metabolic profile of GXB was systematically investigated by UPLC-Q/TOF-MS. Subsequently, quantitative methods for representative xenobiotics in rat plasma and intestine content were respectively validated and developed by UPLC-TQ-MS. Then, the established approaches were successfully applied to characterize the kinetic features of GXB through estimating pharmacokinetic parameters. These results showed that only a few kinds of xenobiotics at low exposure levels were observed in plasma, while various xenobiotics possessed high exposure in intestine content. Among them, steroidal saponins and triterpenoid saponins displayed relatively high exposure in plasma and intestine content, which are likely associated with the therapeutic effects of GXB. Moreover, there were no significant differences between metabolic profiles of GXB and GXB-dePRP, whereas the pharmacokinetic parameters, including area under the concentration–time curve (AUC) and C_max (p < 0.05) for most xenobiotics in GXB were significantly larger than those in GXB-dePRP, implying that the introduction of PRP improved the bioavailability of constituents from TP and AMB. Altogether, this study laid a solid foundation and provided theoretical guidance for further clarification of bioactive components of GXB, as well as the synergistic effect of PRP to the compatibility in GXB.